Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001012525 | SCV001172989 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-02-07 | criteria provided, single submitter | clinical testing | The c.1639delG variant, located in coding exon 4 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 1639, causing a translational frameshift with a predicted alternate stop codon (p.E547Kfs*24). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Centogene AG - |
RCV001809902 | SCV002059483 | likely pathogenic | Endometrial carcinoma | 2021-02-12 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478614 | SCV004221149 | pathogenic | not provided | 2023-02-10 | criteria provided, single submitter | clinical testing | This frameshift variant alters the translational reading frame of the MSH6 mRNA and causes the premature termination of MSH6 protein synthesis. The variant has not been reported in individuals with MSH6-related diseases in the published literature. It also has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. |